 Adjuvant specific active immunotherapy resectable squamous cell lung carcinoma survival analysis Stewart al New York Academy Sciences effectiveness adjuvant specific active immunotherapy lung carcinoma postoperative survival stage carcinoma patients phase II study lung carcinoma-associated antigen TAA complete Freund adjuvant CFA phase III study authors effects specific active immunotherapy conventional management treatment nonspecific immunotherapy patients resectable stages II squamous cell lung carcinoma randomized study control group specific immunotherapy group monthly doses micrograms TAA CFA nonspecific immunotherapy group monthly doses CFA saline patients study skin tests micrograms TAA immunotherapy follow-up patients available life table survival group group group median survivals groups group months group months group months difference significant Cox-Mantel test